Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia

Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. Methods: An economic model was constructed to com...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Becaris Publishing Limited 2023-01-01
coleção:	Journal of Comparative Effectiveness Research
Assuntos:	antimicrobial resistance cost–effectiveness analysis culture and susceptibility habp/vabp health economics imipenem/cilastatin/relebactam infectious diseases
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!